Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Zaremba, Anne [VerfasserIn]   i
 Brinker, Titus Josef [VerfasserIn]   i
Titel:Clinical and genetic analysis of melanomas arising in acral sites
Verf.angabe:Anne Zaremba, Rajmohan Murali, Philipp Jansen, Inga Möller, Antje Sucker, Annette Paschen, Lisa Zimmer, Elisabeth Livingstone, Titus J. Brinker, Eva Hadaschik, Cindy Franklin, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Klaus G. Griewank, Ioana Cosgarea
E-Jahr:2019
Jahr:14 August 2019
Umfang:11 S.
Fussnoten:Gesehen am 06.11.2019
Titel Quelle:Enthalten in: European journal of cancer
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1992
Jahr Quelle:2019
Band/Heft Quelle:119(2019), Seite 66-76
ISSN Quelle:1879-0852
Abstract:Study aim - Melanomas arising in acral sites are associated with a poorer prognosis than other melanoma subtypes. The aim of this study was to evaluate clinical-pathological and genetic characteristics as well as therapeutic responses of a larger cohort of patients with melanomas arising in acral sites. - Methods - Clinical data of 134 patients with melanomas arising in acral sites from the Dept. of Dermatology Essen were collected and analysed with regard to clinicopathological characteristics and treatment responses. Genetic analysis with targeted next-generation sequencing was done on 50 samples. - Results - In our cohort, BRAF (30%), NRAS (28%), TERT promoter (26%), NF1 (14%) and KIT (6%) were frequently identified mutations. Comparing tumours situated on palms and soles with melanomas arising on dorsal acral sites, a higher frequency of NRAS (39.1% versus 25%) and NF1 (17.3% versus 0%) and lower frequencies of BRAF (21.7% versus 75%) and TERT promoter (8.6% versus 50%) mutations were observed. MAPK activating mutations were identified in 64% of tumours. Overall survival was longer in patients treated with immune checkpoint inhibitors as first-line treatment than in patients receiving other systemic therapies (i.e. BRAF/MEK inhibitors and chemotherapy). - Conclusion - Our data suggest that the genetics of melanomas arising in acral sites varies by tumour location and may influence biological behaviour.
DOI:doi:10.1016/j.ejca.2019.07.008
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.ejca.2019.07.008
 Verlag: http://www.sciencedirect.com/science/article/pii/S0959804919304083
 DOI: https://doi.org/10.1016/j.ejca.2019.07.008
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Acral melanoma
 Immune checkpoint inhibitor treatment
 Melanoma treatment
 Melanomas arising in acral sites
 Next-generation sequencing
 promotor mutation
K10plus-PPN:1681152398
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68450931   QR-Code
zum Seitenanfang